Dr. Young Kee Shin (MD, Ph.D) is a distinguished figure in the Korean bio and pharmaceutical industries, renowned for his extensive expertise in companion diagnostics and anti-cancer research. With over 15 years of professorship at a pharmacy school and a proven track record of advising industry stakeholders, Dr. Shin has solidified his position as a leading expert in the field. Since 2010, he has held the roles of Chief Technology Officer (CTO) and Chief Executive Officer (CEO) at ABION Inc, where he is dedicated to developing superior drugs capable of competing on a global scale.

Dr. Shin obtained his medical degree from Seoul National University College of Medicine, followed by a Ph.D. in pathology from the same institution. Since 2004, he has served as a professor at Seoul National University College of Pharmacy. Additionally, since 2016, he has chaired the Department of Molecular Medicine and Biopharmaceuticals at Seoul National University Graduate School of Convergence Science and Technology. Driven by his passion for research, he has authored over 165 SCI/SCIE-level papers, primarily focusing on biomarker-based drug development and biodefense and maintains an impressive H-index of 50. At Seoul National University, he oversees a laboratory in the Department of Molecular Pathology, where he mentors postdoctoral students annually.

Upon joining ABION Inc in 2010, Dr. Shin led efforts in companion diagnostics and biomarker-based anti-cancer drug development. Subsequently, he assumed leadership of the Anti-Cancer Drug Companion Diagnostic Technology Development Project at the Ministry of Science in 2013. During his three-year tenure, he guided the project team in supporting the establishment and initial research of companion diagnostic companies. In 2014, he contributed his expertise as a companion diagnostic expert at the Central Pharmaceutical Review Committee of the Ministry of Food and Drug Safety, evaluating novel companion diagnostic technologies and targeted anticancer drugs.

At ABION, Dr. Shin has successfully cultivated a robust pipeline of targeted anti-cancer drugs based on representative biomarkers. Additionally, he actively engages in research across diverse therapeutic areas, including immune cytokines and gene therapy.